Charles River Laboratories International CRL
Healthcare · Medical - Diagnostics & Research · Synthos Deep Dive · 2026-07-03
The Overview
Charles River is the company drug-makers hire to do the early, unglamorous lab work before a new medicine can be tested in people — it breeds the specialized research mice and rats, runs the safety and toxicology studies, and tests that manufactured drugs are clean. It is very good at this and hard to replace. But its customers — pharma and biotech companies — have been cutting their research budgets, so Charles River's sales have stopped growing and are actually shrinking a little this year.
Is the stock cheap or expensive? Roughly fair, maybe a touch full. It jumped almost 50% in the past year and is sitting right at its highest price in 12 months, and the professional analysts' average price target is actually a hair below where it trades today. So you'd be buying after the pop, not before it.
Our verdict is Watch — a good company to keep an eye on, but not one to buy at today's price. Wait for either a cheaper price or clear evidence that its customers are spending on research again.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit elevated). The stock swings more than the market, has fallen ~50% from a past peak, and just spiked to a high — a stumble could hurt.
- Growth Quality 3/10 (weak right now). Sales are flat-to-shrinking and profit margins are getting squeezed. The business is high-quality but currently going backwards.
- Exponential Potential 2/10 (low). This is a mature, slow-moving market — not the kind of company that doubles quickly.
The one big worry: if drug companies keep their research spending tight, Charles River's most important business (safety testing) stays soft and earnings don't recover.
Putting a number on it: our fair-value estimate is $220 against a current price of $291.50 — a premium price for a business we still like.
Our summary metrics
Modest fwd P/E (~21×) but cyclical CRO, beta 1.45, −50% peak drawdown, RSI 84 near 52-wk high, net-debt/clean-EBITDA ~3.8×.
Revenue flat-to-declining (organic −1% to −0.5% guided), margins compressing, FY25 GAAP loss, ROIC ~7% — a low-growth cyclical, not a compounder.
Growth decelerating/negative, no acceleration, mature CRO end-market — minimal exponential optionality.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Growth decelerating/negative, no acceleration, mature CRO end-market — minimal exponential optionality.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $222.11 (high $250 / low $192; 1 Strong Buy · 26 Buy · 10 Hold · 0 Sell) — context; note it sits BELOW the current price |
| Valuation | Neg. GAAP EPS (FY25 loss) · ~21× FY26E non-GAAP · ~19× FY27E · ~15× FY30E · EV/S 3.5× · EV/EBITDA ~19× (clean) |
| Technicals | Overbought — $230.69 at the 52-wk high, RSI 84, +28% above both 50- & 200-DMA (~$180), +49% 12-mo, but −50% max drawdown history |
| Conviction | Low — 0 expert voices in KB, 0 traceable claims; verdict rests entirely on fundamentals + quant |
| Position sizing | Not a buy here; watch-list only until a pullback or a demand inflection |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for CRL — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $291.50, 19% above the 50-day average ($245), 48% above the 200-day average ($197) — an uptrend. 2% below the 52-week high of $299, 100% above the 52-week low of $146.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $291.50 is currently inside the band (band $242–$317).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 68.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.77, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = CRL · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Charles River Laboratories (NYSE: CRL), founded 1947, headquartered in Wilmington, MA, is the world's leading contract research organization (CRO) for early-stage drug development. It sits at the very front of the pharma value chain — before human trials — and reports in three segments. Fiscal year ends late December.
Revenue mix — by segment (FY2025, from filings):
- Discovery & Safety Assessment (DSA): $2.40B (60%) — the earnings engine: toxicology, pathology, safety pharmacology, bioanalysis, DMPK, and early discovery services. This is the most cyclical piece, tied directly to biopharma R&D budgets.
- Research Models & Services (RMS): $846M (21%) — the crown-jewel moat: purpose-bred rodent research models (specialized rat/mouse strains), genetically engineered models, and insourcing services. Highest-margin, hardest-to-replicate franchise.
- Manufacturing Solutions: $766M (19%) — quality-control testing (endotoxin/microbial, biologics testing) and avian vaccine (SPF egg) services. The steadiest, most recurring segment.
Revenue mix — by geography (FY2025, from filings):
- United States $2.14B (~53%) · Europe $1.10B (~27%) · Canada $501M (~12%) · Asia Pacific $205M (~5%). US-centric but meaningfully global.
What changed in 2026: management completed the divestiture of the CDMO and Cell Solutions businesses (to GI Partners, closed May 2026) and is selling certain European Discovery Services sites — a deliberate refocus on core regulated drug-development testing. This is why reported revenue is guided down ~4–5.5% in 2026 (divestitures + FX), on top of a slightly negative organic trend.
2. The expert thesis
There is no expert coverage of CRL in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top list is empty. No named investor or analyst voice in our distilled KB has taken a traceable position on this name.
Per house standard, we do not fabricate conviction. This verdict is therefore entirely fundamentals- and quant-driven: it rests on the reported financials, management's own dated guidance (§9, half-weighted), the analyst-estimate consensus (labeled as estimates), and the technicals — with zero borrowed conviction from experts. Where a name like LLY earns a "High" conviction rating from 13 reconciled voices, CRL earns "Low" by construction: the absence of coverage is itself information, and we grade it honestly rather than inventing a thesis.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Elevated | Forward P/E ~21× is not egregious, but beta 1.45, a −50% historical peak drawdown, RSI 84 at the 52-wk high, and net-debt/clean-EBITDA ~3.8× on a declining revenue base make the risk asymmetric here. |
| Growth Quality | 3 · Weak | Revenue flat-to-declining (management guides FY26 organic revenue −1.5% to −0.5%), non-GAAP margins compressing (Q1'26 op margin 16.3% vs 19.1%), a GAAP net loss in FY25, and ROIC ~7%. A quality franchise in a low-quality moment. |
| Exponential Potential | 2 · Low | Growth is decelerating, not accelerating; the CRO end-market is mature; no credible path to multibagger growth from here. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Biopharma R&D spending re-accelerates; DSA bookings inflect; portfolio refocus lifts margins. FY27E non-GAAP EPS beats to ~$13.5 (vs ~$12.3 cons); multiple re-rates to a growth ~22×. | ~$300 (+30%) |
| Base (our anchor) | Guidance roughly holds — 2026 organic revenue flat-to-slightly-down, then a slow recovery; FY27E non-GAAP EPS ~$12.3; a cyclical-trough CRO earns a ~18× multiple. | ~$220 (−5%) |
| Bear | R&D downturn deepens; DSA demand stays soft, NHP-supply/pricing overhang persists; FY26 EPS lands at the low end (~$10.80) and the multiple de-rates to ~15×. | ~$165 (−28%) |
Synthos fair value = the base case, ~$220 (−5%), with the full $165–$300 span as the honest range. Our base sits essentially on top of the Street's $222 consensus — and notably, both are below the current $230.69 price. The stock has run ahead of its own fundamentals into the print. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). CRL is neither at present — it is a cyclical in a trough:
- Forward growth: revenue CAGR FY25→FY30E is only ~1.2% ($4.02B → $4.25B on consensus); non-GAAP EPS CAGR ~8% ($10.28 → ~$15.30) — driven more by buybacks, cost cuts, and mix than by volume.
- Acceleration (the 2nd derivative) is negative: revenue went $4.13B (FY23) → $4.05B (FY24) → $4.02B (FY25), and management guides FY26 organic revenue down another 0.5–1.5%. This is the opposite of the accelerating profile we reward — CRL is decelerating into a downturn, not inflecting up.
- Room to run: the global preclinical-CRO TAM is large but mature and slow-growing; CRL is already the category leader in research models, so share gains are incremental, not explosive. An $11B leader in a low-single-digit-growth market does not have a multibagger runway from operations.
- Reinvestment runway: capex is disciplined (~$219M, ~5% of revenue) and FCF is healthy (~$518M FY25) — but capital is going to buybacks ($360M repurchased FY25, $200M in Q1'26 alone) rather than high-return growth reinvestment, which is the correct call for a low-growth cash generator but confirms this is not an exponential.
Exponential Potential: Low (2/10). The optionality here is cyclical recovery, not secular acceleration. Own it (if at all) for a demand-cycle turn and capital returns, never for a fast multibagger.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $4.02B, −0.9% (FY24 $4.05B, −2.0% on FY23 $4.13B). Three straight years of flat-to-down top line — the cyclical downturn is real and reported.
- Quarterly trajectory: Q1'25 $984M → Q2 $1,032M → Q3 $1,005M → Q4 $994M → Q1'26 $996M (+1.2% YoY reported, but −1.5% organic). Stabilizing, not yet recovering.
- Margins: gross ~31.9% TTM; GAAP operating margin depressed by divestiture/impairment charges; non-GAAP Q1'26 operating margin 16.3% (down from 19.1% a year ago) — compressing, driven by higher DSA study costs, unfavorable RMS mix, and executive-transition stock comp.
- Earnings: FY25 GAAP net loss −$144M (−$2.91 EPS) — swung negative on ~$500M+ of divestiture/impairment charges, especially the Q4'25 non-cash hit. On a non-GAAP basis FY25 EPS was ~$10.28; FY26 is guided to $10.80–$11.30. Read GAAP and non-GAAP side by side here — the gap is charges, not operations.
- Cash flow: operating CF $738M, capex −$219M, FCF ~$518M FY25 (FCF yield ~4.7%). The cash engine is intact even as the P&L takes charges — a key quality tell.
- Balance sheet: total debt ~$3.07B, cash $214M, net debt ~$2.85B. On the impairment-depressed GAAP TTM EBITDA the net-debt/EBITDA optically screens ~9.9× — misleading; on clean/normalized EBITDA (~$780M) leverage is ~3.6–3.8×, elevated but serviceable given steady FCF. Current ratio 1.36×.
6. Valuation — priced in or room?
On the headline, CRL screens cheap — but the cheapness is a mirage created by charges. GAAP EPS is negative, so trailing P/E is meaningless. On the numbers that matter (non-GAAP, forward): ~21× FY26E → ~19× FY27E → ~15× FY30E, with EV/S 3.5× and clean EV/EBITDA ~19×. That is a fair-to-full multiple for a business whose revenue is shrinking — you're paying a normal-growth multiple for sub-1% revenue growth. A reverse read: today's ~$231 implies the market is already pricing a demand recovery and margin re-rate that has not yet shown up in the bookings. Street targets (context): consensus $222.11, high $250, low $192 — and critically the consensus sits below the current price, i.e. the average analyst thinks the stock is slightly ahead of itself too. FMP's letter rating is C (overall score 2/5), with weak marks on ROE, ROA, and P/E. Not a value buy at $231; fair-to-full, which is exactly why the verdict is Watch, not Buy.
7. Technicals (from the tech block)
- Trend: up, and stretched. $230.69 sits ~28% above both the 50-DMA ($180.4) and 200-DMA ($180.4) — a very wide gap that tends to mean-revert. MACD +13.8 (positive).
- Location: at the 52-week high (0% from high), +58% off the 52-week low ($145.6) — but the history carries a −50% max drawdown from peak, a reminder of how violently this cyclical can de-rate.
- Momentum: RSI(14) 83.9 — clearly overbought (>70). This is a stretched-entry warning, not a green light.
- Relative strength: CRL +49.4% 12-mo vs SPY +20.6% and QQQ +30.3%; +31.9% 3-mo vs SPY +13.7%. Strong recent outperformance — but it has run into a soft fundamental backdrop, which is the tension in the whole thesis.
- Read: technicals say "great trade recently, bad entry now." An RSI-84 print at the 52-wk high, ~28% above the moving averages, with the Street target below spot, is a textbook wait-for-pullback setup. A retracement toward the $180 moving-average cluster would be a far lower-risk entry.
8. Moat & competitive position
CRL's moat is real and, in one segment, exceptional. Research Models & Services is a near-oligopoly: breeding specific-pathogen-free, genetically defined rodent strains at scale, with the regulatory pedigree and biosecurity that drug developers require, is extraordinarily hard to replicate — CRL is the global #1. DSA (safety assessment) is a scale-and-reputation moat: regulators and sponsors trust a small set of GLP-compliant providers, and switching costs mid-program are high. The vulnerability is that DSA is demand-cyclical — it rises and falls with biopharma R&D budgets and biotech funding — and faces a specific overhang in non-human-primate (NHP) supply costs/legal matters that has pressured margins. Manufacturing Solutions (endotoxin/microbial QC, biologics testing) is the steadiest, most recurring piece.
Peer set (market cap, from FMP): Revvity $12.7B, Baxter $11.7B, Penumbra $12.5B, DaVita $15.1B, Bio-Rad $8.0B, Qiagen $8.3B, Avantor $7.0B, Caris Life Sciences $5.2B. (FMP's peer list is a broad "diagnostics & research / med-tech" bucket rather than pure preclinical-CRO comps — CRL's truest public comparables are the clinical CROs like ICON and IQVIA and tools names like Thermo Fisher, which are not in this list.) Within the group CRL has a stronger franchise moat than most but weaker current growth.
9. Management, capital allocation & guidance
- Leadership: long-time chairman/founder-era executive James C. Foster remains a director; Birgit Girshick is now Chief Executive Officer — a leadership transition that is itself a source of elevated stock-comp expense in the near term (flagged in the Q1'26 release).
- Capital allocation: disciplined and shareholder-return-tilted — $360M of buybacks in FY25 and another $200M in Q1'26, with $800M remaining on a $1.0B authorization. No dividend. Portfolio pruning (CDMO/Cell Solutions divested to GI Partners; European Discovery sites being sold) to refocus on core regulated testing. Appropriate for a low-growth cash generator, though buying back stock at the 52-wk high with RSI 84 is not obviously well-timed.
- Insider activity: the most recent Form 4 shows director James Foster selling 75,000 shares at $225 on 2026-06-29 (filed 2026-07-01), alongside a cluster of gift transfers in early June. A large discretionary insider sale into the price spike is a mild negative-to-neutral signal worth noting — not alarming on its own, but not a vote of confidence at these levels.
- Management's own guidance (the earnings-call track, HALF-WEIGHTED — this is management's self-interested book): the SEC 8-K (Item 2.02) earnings release dated 2026-05-07 is a real earnings release and reaffirms 2026 guidance: reported revenue growth −5.5% to −4.0% (divestitures + FX), organic revenue −1.5% to −0.5%, GAAP EPS ~$5.35, non-GAAP EPS $10.80–$11.30. CEO Girshick framed the DSA demand environment as "tracking to our expectations" with "solid bookings," and positioned the year as "improving results over the course of the year." Taken at half-weight: management is guiding to a declining top line and a flat-ish bottom line — consistent with our trough read, and notably not a growth story.
10. Catalysts & what to watch
- Next earnings: 2026-08-05 (Q2'26; Street EPS $2.72, revenue ~$978M). The line that matters: DSA bookings and net book-to-bill — the leading indicator of whether the demand trough is turning.
- Biopharma R&D / biotech funding cycle: the single macro driver of DSA. Watch biotech funding, XBI, and large-pharma R&D-budget commentary.
- Margin trajectory: whether non-GAAP operating margin stabilizes off the Q1'26 16.3% low as restructuring savings land.
- NHP supply overhang: resolution (or escalation) of the non-human-primate sourcing cost/legal matter.
- Buyback pace & portfolio actions: completion of the European Discovery Services divestiture and continued repurchases.
Thesis tripwires (what would change the call): toward Buy — two consecutive quarters of positive DSA book-to-bill AND a pullback toward the ~$180 moving-average cluster; toward Avoid — organic revenue declines widen beyond guidance, non-GAAP margin breaks below ~15%, or FCF conversion deteriorates.
11. Key risks
- Cyclical demand (structural-cyclical): DSA — 60% of revenue and the earnings driver — rises and falls with biopharma R&D budgets and biotech funding. A prolonged downturn is the core risk.
- Valuation/technical: RSI 84 at the 52-wk high, ~28% above the moving averages, with the Street target below spot — poor risk/reward on entry timing.
- Margin compression: non-GAAP operating margin fell to 16.3% (Q1'26) on study-cost and mix pressure plus executive-transition comp; recovery is not yet proven.
- Leverage on a declining base: ~3.6–3.8× clean net-debt/EBITDA is manageable but leaves less cushion if EBITDA slips further.
- NHP supply / legal overhang: non-human-primate sourcing costs and related legal matters have pressured DSA and could recur.
- No expert corroboration: unlike a conviction-track name, there is zero KB coverage to cross-check the fundamental read — the verdict leans entirely on quant + guidance.
12. Verdict, position sizing & monitoring
Watch. Charles River is a genuinely high-quality, wide-moat franchise — the world's leading research-model and preclinical-safety business — but it is a cyclical caught in a demand trough, and after a ~49% twelve-month run it now trades at fair-to-full value, at its 52-week high, with RSI 84 and the Street's own price target below the market price. The fundamentals (three years of flat-to-declining revenue, management guiding 2026 organic revenue down, compressing non-GAAP margins, a FY25 GAAP loss) do not support chasing it here. There is no expert conviction in the KB to override the quant read, and the quant read says "wait."
- Sizing: watch-list only — no position at $231. The right entry is either a pullback toward the ~$180 moving-average cluster or clear evidence (positive DSA book-to-bill for two quarters) that the demand trough has turned. If both align, this becomes a credible cyclical-recovery Buy.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score at the 2026-08-05 print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $230.69.
- Single biggest risk: a prolonged biopharma R&D-spending downturn keeps DSA demand — the earnings engine — soft, so the low-single-digit "recovery" already embedded in the price fails to arrive.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of CRL in the Synthos knowledge base, so no
claim_ids are cited and none are fabricated. This verdict is fundamentals- and quant-driven by construction, with management guidance half-weighted. - Data as-of: fundamentals 2026-03-28 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K earnings release dated 2026-05-07. Forward figures are analyst consensus and/or management guidance (FMP/SEC), explicitly labeled as estimates.
- GAAP vs non-GAAP caveat: FY25 GAAP EPS is a loss (−$2.91) driven by divestiture/impairment charges; operating/valuation discussion uses non-GAAP EPS (~$10.28 FY25; $10.80–$11.30 guided FY26), which we flag as management-defined adjusted figures.
- Management caveat: CRL management's guidance is management's own self-interested book, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").